Source: Annual Congress 2008 - Novel mechanisms and targets of molecular pulmonary pathology
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
N. M. Korthagen, C. H. M. van Moorsel, N. P. Barlo, H. J. T. Ruven, J. M. M. van den Bosch, J. C. Grutters (Nieuwegein, Netherlands). High serum levels of YKL-40 in IPF. Eur Respir J 2008; 32: Suppl. 52, 3536

Member's Comments

No comment yet.

Related content which might interest you: Elevated serum S100A4 levels in patients with silicosis Source: International Congress 2019 – New mechanistic insights into pulmonary fibrosis Year: 2019 Usefulness of serum procalcitonin in lung cancer patients with elevated serum C-reactive protein level Source: Annual Congress 2011 - Instructive clinical aspects of lung cancer Year: 2011 Serum markers of IPF Source: Research Seminar 2004 - Genotyping and Phenotyping of Diffuse Parenchymal Lung Diseases Year: 2004 Elevated serum IL-8: a biomarker indicating exacerbation-prone COPD Source: International Congress 2017 – COPD biomarkers Year: 2017 High serum periostin levels and the association with pulmonary tuberculosis Source: International Congress 2018 – Diagnosis of tuberculosis Year: 2018 Serum and BALF levels of YKL-40 in patients with alveolar proteinosis Source: Annual Congress 2010 - Biomarkers in diffuse parenchymal lung disease Year: 2010 Determinants of serum leptin and adiponectin levels in patients with COPD Source: Eur Respir J 2005; 26: Suppl. 49, 59s Year: 2005 The relationship between the serum YKL-40 level and severity of asthma Source: Annual Congress 2012 - Asthma management Year: 2012 Serum osteoprotegerin and fibulin-1 levels negatively correlate with DLCO in IPF Source: International Congress 2019 – Biomarkers of idiopathic interstitial pneumonia Year: 2019 Characterisation of asthma subgroups associated with circulating YKL-40 levels Source: Eur Respir J, 50 (4) 1700800; 10.1183/13993003.00800-2017 Year: 2017 Comparative study of CC16, KL-6 and SP-D as serum markers in sarcoid patients Source: Eur Respir J 2002; 20: Suppl. 38, 173s Year: 2002 Serum neopterin and IL-6 as biomarkers in patients with COPD. Source: International Congress 2017 – Novel molecular and genetic targets in COPD Year: 2017 Role of serum adiponectin in COPD Source: Annual Congress 2008 - Biomarkers and disease assessment in COPD Year: 2008 Serum KL-6 as a marker of disease progression in SSc-ILD Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: from the bench to the bedside Year: 2018 High level of serum SP-D with normal range of KL-6 predicts a good prognosis of patients with fibrotic changes on HRCT Source: Annual Congress 2010 - Biomarkers in diffuse parenchymal lung disease Year: 2010 Plasma levels of soluble RAGE are lower in COPD Source: Annual Congress 2009 - COPD and asthma - from the cell to the clinic Year: 2009 KL-6 serum levels in adult cystic fibrosis patients Source: Annual Congress 2011 - Cystic fibrosis: clinical and laboratory studies Year: 2011 Serum levels of TIMP-1 and TIMP-2 are elevated in patients with pulmonary hypertension Source: Eur Respir J 2003; 22: Suppl. 45, 463s Year: 2003 Serum concentrations of KL-6 in patients with IPF and lung cancer and serial measurements of KL-6 in IPF patients treated with antifibrotic therapy Source: Virtual Congress 2021 – Biomarkers and e-health in idiopathic interstitial pneumonia Year: 2021 Serum KL-6, SP-D and MMP-2 as diagnostic biomarkers in asbestosis and silicosis Source: International Congress 2017 – Silicosis has not gone away Year: 2017